HK1006812A1 - Stabilized hydrophobic protein formulations - Google Patents

Stabilized hydrophobic protein formulations

Info

Publication number
HK1006812A1
HK1006812A1 HK98106061A HK98106061A HK1006812A1 HK 1006812 A1 HK1006812 A1 HK 1006812A1 HK 98106061 A HK98106061 A HK 98106061A HK 98106061 A HK98106061 A HK 98106061A HK 1006812 A1 HK1006812 A1 HK 1006812A1
Authority
HK
Hong Kong
Prior art keywords
protein formulations
hydrophobic protein
stabilized hydrophobic
stabilized
formulations
Prior art date
Application number
HK98106061A
Other languages
English (en)
Inventor
Thomas C Boone
William C Kenney
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23093007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1006812(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of HK1006812A1 publication Critical patent/HK1006812A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK98106061A 1988-12-16 1998-06-23 Stabilized hydrophobic protein formulations HK1006812A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/285,159 US5104651A (en) 1988-12-16 1988-12-16 Stabilized hydrophobic protein formulations of g-csf

Publications (1)

Publication Number Publication Date
HK1006812A1 true HK1006812A1 (en) 1999-03-19

Family

ID=23093007

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98106061A HK1006812A1 (en) 1988-12-16 1998-06-23 Stabilized hydrophobic protein formulations

Country Status (10)

Country Link
US (1) US5104651A (fr)
EP (1) EP0373679B1 (fr)
JP (1) JP2888969B2 (fr)
AT (1) ATE107513T1 (fr)
AU (1) AU621695B2 (fr)
CA (1) CA2005143C (fr)
DE (1) DE68916385T2 (fr)
ES (1) ES2055001T3 (fr)
HK (1) HK1006812A1 (fr)
WO (1) WO1990006762A1 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE69233451T2 (de) * 1991-06-20 2006-01-12 Aventis Behring L.L.C. Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
EP0582932A1 (fr) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Système thérapeutique pour l'administration parentérale de facteurs de croissance hématopoietiques
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
CA2092271C (fr) * 1993-03-09 2009-10-13 Eddie Reed Utilisation de fsc-g pour traiter les effets secondaires du taxol
EP0791061A4 (fr) * 1994-03-04 1998-07-15 Ludwig Inst Cancer Res Animaux a rupture genique ciblee
USRE38424E1 (en) 1994-11-21 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Method for treating taxol side-effects with G-CSF
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
DK1129720T3 (da) 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
DE60139339D1 (de) * 2000-11-07 2009-09-03 Novartis Vaccines & Diagnostic Stabilisierte interferonzusammensetzungen
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
JP4444652B2 (ja) * 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
WO2004099231A2 (fr) 2003-04-09 2004-11-18 Neose Technologies, Inc. Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
WO2004020462A1 (fr) 2002-08-27 2004-03-11 Fujii, Nobutaka Antagoniste de cxcr4 et son utilisation
US7273921B2 (en) * 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
CA2519092C (fr) * 2003-03-14 2014-08-05 Neose Technologies, Inc. Polymeres hydrosolubles ramifies et conjugues de ceux-ci
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
AU2004240553A1 (en) * 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) * 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
EP2140875A1 (fr) 2003-10-24 2010-01-06 Nora, LLC Compositions et méthodes pour une grossesse en santé
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
CA2547140A1 (fr) * 2003-11-24 2005-06-09 Neose Technologies, Inc. Erythropoietine glycopegylee
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20070254836A1 (en) * 2003-12-03 2007-11-01 Defrees Shawn Glycopegylated Granulocyte Colony Stimulating Factor
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005056760A2 (fr) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Hormone stimulant le follicule humain glycopegyle
NZ548123A (en) * 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
EP1771066A2 (fr) 2004-07-13 2007-04-11 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon glp-1
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
EP1799249A2 (fr) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Interferon alpha glycopegyle
US20080176790A1 (en) * 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
WO2006055260A2 (fr) * 2004-11-05 2006-05-26 Northwestern University Utilisation de scf et de scf dans le traitement de l'ischemie cerebrale et des troubles neurologiques
US9029331B2 (en) * 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (fr) 2005-04-08 2010-03-31 Biogenerix Ag Compositions et méthodes utilisées pour la préparation de mutants par glycosylation de l'hormone de croissance humaine résistant à la protéase
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
JP5216580B2 (ja) * 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
JP5137821B2 (ja) * 2005-06-01 2013-02-06 マキシジェン， インコーポレイテッド Ｐｅｇ化されたｇ−ｃｓｆポリペプチドおよびその製造方法
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP1937719A4 (fr) * 2005-08-19 2010-11-24 Novo Nordisk As Facteur vii et facteur viia glycopégylé
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
DE102006009437A1 (de) 2006-03-01 2007-09-13 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
RU2322452C2 (ru) * 2006-03-27 2008-04-20 Михаил Николаевич Смирнов Иммуномодулирующая композиция
US20080242607A1 (en) * 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5457185B2 (ja) * 2006-10-04 2014-04-02 ノヴォ ノルディスク アー／エス グリセロール連結のｐｅｇ化された糖および糖ペプチド
EP3011961B1 (fr) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 pour la mobilisation des cellules hématopoiétiques progénitrices en vue d'une transplantation
DK2144923T3 (da) * 2007-04-03 2013-05-13 Biogenerix Ag Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
WO2008151258A2 (fr) * 2007-06-04 2008-12-11 Neose Technologies, Inc. Glycosylation à liaisons o utilisant des n-acétylglucosaminyl transférases
WO2008154639A2 (fr) * 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
EP2581441A1 (fr) 2007-08-09 2013-04-17 Genzyme Corporation Procédé de traitement d'une maladie auto-immune avec des cellules souches mésenchymateuses
EP2076243B9 (fr) 2007-08-27 2015-01-14 ratiopharm GmbH Formulation liquide du g-csf
DE102007040932A1 (de) 2007-08-27 2009-03-05 Biogenerix Ag Flüssigformulierung von G-CSF
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US8758761B2 (en) * 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
CA2715465C (fr) 2008-02-27 2017-03-21 Novo Nordisk A/S Molecules de facteur viii conjuguees
WO2010092571A2 (fr) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Peptides courts dérivés de bêta-défensine
JP5715622B2 (ja) 2009-06-14 2015-05-07 バイオカイン セラピューティックス リミテッド 血小板レベルを増大させるためのペプチド療法
EP2399572A1 (fr) 2010-06-22 2011-12-28 Sandoz AG Stockage à long terme de G-CSF humain recombinant non glycosylé
EP2841084B1 (fr) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Peptide antagoniste de cxcr4 et son utilisation pour le traitment de tumeurs pulmonaires
EA201791717A1 (ru) 2012-09-07 2018-03-30 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
JP6525171B2 (ja) 2015-04-13 2019-06-05 国立研究開発法人産業技術総合研究所 環状化サイトカイン及びその製法
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
KR102033920B1 (ko) 2016-02-23 2019-10-18 바이오라인알엑스 리미티드 급성 골수성 백혈병을 치료하는 방법
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
WO2018138267A1 (fr) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Procede de determination de l'efficacite d'une composition comprenant le g-csf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
AU1234383A (en) * 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
CA1297003C (fr) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition et methode pour traiter les animaux
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor

Also Published As

Publication number Publication date
JPH03502808A (ja) 1991-06-27
ES2055001T3 (es) 1994-08-16
EP0373679B1 (fr) 1994-06-22
AU4668989A (en) 1990-07-10
CA2005143A1 (fr) 1990-06-16
ATE107513T1 (de) 1994-07-15
WO1990006762A1 (fr) 1990-06-28
US5104651A (en) 1992-04-14
EP0373679A2 (fr) 1990-06-20
DE68916385D1 (de) 1994-07-28
DE68916385T2 (de) 1994-10-13
EP0373679A3 (fr) 1991-04-17
JP2888969B2 (ja) 1999-05-10
CA2005143C (fr) 1995-07-11
AU621695B2 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
HK1006812A1 (en) Stabilized hydrophobic protein formulations
HUT51617A (en) Process for producing oxadiazole derivatives and pharmaceutical preparations containing these compounds as active substance
HU900708D0 (en) Process for preparation of substituted 1,3-oxathiolanes and pharmaceutical preparations containing them
AU4105985A (en) Implantable formulations of regulatory peptides with controlled release
AU9130691A (en) Stable suspension formulations for controlled delivery of pharmaceutical compounds
AU6973987A (en) C(29)-carbonyloxymilbemycin derivatives for controlling parasitic pests of animals and plants
IL88460A0 (en) Stabilized medicinal substances,a process for the preparation thereof,and stable medicinal formulations
HUT62201A (en) Method for producing galen preparations containing cyclosporines as active ingredient
AU1164188A (en) Multi-component long-acting medicament formulation for implantation
HU907939D0 (en) Stabilized aqueous formulations of small peptides
HUT50141A (en) Herbicide compositions containing isoxazoline derivatives as active components and process for producing isoxazoline derivatives
EP0390930A4 (en) Stable aqueous preparation of active vitamin d 3?
IE880183L (en) Thrombin preparations
GB2183632B (en) Dihydropyrimidine derivatives for the growth of hair and cosmetic formulations containing such compounds
AU2623688A (en) Oral formulation of buspirone and salts thereof
AU4298289A (en) Method for the preparation of a biologically active substance
AU1823588A (en) Novel compounds and their preparations and formulations
IL87778A (en) Topical pharmaceutical compositions in the form of a hydrogel containing stabilized therapeutically active proteins and their preparation
AU586535B2 (en) Artificial hair for hair implantation and method of preparation thereof
HUT40791A (en) Process for preparing optically active azolyl-carbinol derivatives and pharmaceutical preparations comprising such compounds
HU907361D0 (en) Process for the production of /n-(gamma-glutamyl)-glycyl/-alanine derivatives and medical preparations containing them
CS700388A1 (en) Method of methyliminoacetate's hydrochloride preparatio(
AU617427C (en) Pharmaceutical growth hormone formulations
BG44221A1 (en) Composition for formulating of pesticide preparations
AU109567S (en) Tray for presentation of pharmaceutical formulations

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20091217